| Project/Area Number |
17K17066
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 急性腎障害 / ランソプラゾール / NRF2 / シスプラチン腎症 / 虚血再灌流障害 / 集中治療医学 |
|---|
| Outline of Final Research Achievements |
There is currently no treatment for acute kidney injury and we have identified lansoprazole as a potential therapeutic agent. We hypothesized that lansoprazole would have antioxidant properties and be protective to the kidneys. We investigated whether lansoprazole would be protective against acute kidney injury, but failed to demonstrate a protective effect in an acute kidney injury model, and found that lansoprazole may have a protective effect on the kidneys in vitro. In this study, it was difficult to find sufficient time for research due to the tight clinical situation caused by the COVID-19 epidemic. It is hoped that further experiments will demonstrate a protective effect against acute kidney injury.
|
| Academic Significance and Societal Importance of the Research Achievements |
急性腎障害はさまざま原因で生じるが治療薬がなく、慢性腎障害に移行し透析導入が必要となる危険性がある。また、透析導入患者は年々増加しており、医療費も年々増加している。現在において、急性腎障害に対する治療薬を開発するのは急務である。そのため、本研究によりin vitroでランソプラゾールが急性腎障害への治療薬への可能性が見出すことができたことは大きい。今後、さらなる実験系により急性腎障害への保護的作用とメカニズムを明らかにすることができればよい。
|
